

10/501891

DT 1000'd POTS/RTS 20 JUL 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : National Phase Application of PCT/GB03/00211  
Applicant : Karel DOREY et al.  
Filed : Herewith  
TC/A.U. :  
Examiner :  
  
Docket No. : 3198-102  
Customer No. : 06449  
Confirmation No. :

## **INFORMATION DISCLOSURE STATEMENT**

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. The publications, which are listed on the attached Form 1449, were cited in an International Search Report (copy attached herewith) in corresponding International Application No. PCT/GB03/00211. Applicants believe that the Patent and Trademark Office should have copies of these publications from the ISA. If, however, the publications are missing from files, Applicants will provide copies, if notified.

Respectfully submitted,

By John Smith

Jeffrey L. Ihnen

## Attorney for Applicants

Registration No. 28,957

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005

Telephone: (202)783-6040

10/501891

DT15 Rec'd PCT/PTO 20 JUL 2004

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

<i>Complete &amp; Known</i>	
Application Number	National Phase Application of PCT/GB03/00211
Filing Date	Herewith
First Named Inventor	Karel DOREY et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	3198-102

Sheet

1

of

2

**Attorney Docket Number**

3198-102

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
		WO	01/94408		Europe Molecular Biology Lab	12-13-2001	
		WO	03/031608	A	Susan Branford et al.	04-17-2003	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

**For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** <sup>5</sup>Kind

1. Separately, patient documents, the indication of the year of the filing of the Empire must precede the date, number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Completed

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	National Phase Application of PCT/GB03/00211
				Filing Date	Herewith
				First Named Inventor	Karel DOREY et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	3198-102

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Barila, D. et al., "An Intramolecular SH3-Domain Interaction Regulates C-ABL Activity", Nature Genetics, Vol. 18, March 1998, pp. 280-282	
		Dorey, K., et al., "Regulation of Human C-Abl Tyrosine Kinase Activity in Xenopus Oocytes and Acceleration of Progesterone-Induced G2/M Transition By Oncogenic Forms", Biological Chemistry, Vol. 380, No. 2, February 1999, pp. 223-230	
		Dorey, Karel et al., "Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.", Oncogene, Vol. 20, No. 56, Dec. 6, 2001, pp. 8075-8084	
		Pluk, Helma et al., "Autoinhibition of c-Ab1", Cell, Vol. 108, No. 2, Jan. 24, 2002, pp. 247-259	
		Topaly, J. et al., "Synergistic Activity of the New ABL-Specific Tyrosine Kinase Inhibitor ST1571 and Chemotherapeutic Drugs on BCR-ABL-Positive Chronic Myelogenous Leukemia Cells", Leukemia, Vol. 15, May 2001, pp. 342-347	
		Van Etten, Richard A., "Cycling, stressed-out and nervous: Cellular functions of c-Abl", Trends in Cell Biology, Vol. 9, No. 5, May 1999, pp. 179-186	
		Walkenhorst, Jeurgen et al., "Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe.", Oncogene, Vol. 12, No. 7, 1997, pp. 1513-1520	
		Wen, S-T et al., "The PAG gene product, a stressed-induced protein with antioxidant properties, is an Ab1 SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity", Genes and Development, Vol. 11, No. 19, October 1, 1997, pp. 2456-2467	
		Wu, J.J. et al., "Comparison of the intrinsic kinase activity and substrate specificity of c-Abl and Bcr-Abl" Bioorganic and Medicinal Chemistry Letters, Vol. 8, No. 17, September 8, 1998, pp. 2279-2284	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.